BTIG Affirms Celgene (CELG) at 'Buy'; Sees Potential Operating Leverage as 'Underappreciated'
Tweet Send to a Friend
BTIG affirms Celgene Corporation (Nasdaq: CELG) with a Buy rating and $140 price target and comments on medium-term expectations for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
